Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04534205
Title A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors BioNTech SE
Indications

oropharynx cancer

laryngeal squamous cell carcinoma

oral squamous cell carcinoma

head and neck squamous cell carcinoma

hypopharynx cancer

Therapies

BNT113 + Pembrolizumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.